Patent US5656739A successfully refreshed from Google Patents.
← Back to Patent Explorer
US5656739A Expired / Lapsed US ⏱️ 0.0 years remaining

Nucleotide-directed assembly of bimolecular and multimolecular drugs and devices

Assignee: Molecular Machines Inc
•
Filing: 1995-06-07
•
Granted: 1997-08-12
•
Expires: 2015-06-07
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Methods of producing synthetic heteropolymers and multivalent heteropolymeric hybrid structures capable of assembling non-oligonucleotide molecules are provided. These structures are used to direct the assembly of multimolecular complexes. A number of synthetic heteropolymers, multivalent heteropolymeric hybrid structures and multimolecular complexes are also provided.

Inventors

  • 👤 Roger S. Cubicciotti

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-29 05:19
CPC Classifications
C; C12; C12Q; C12Q1/00; C12Q1/68; C12Q1/6811; C07; C07H; C07H21/00; C12N; C12N9/00; Y; Y10; Y10T; Y10T436/00; Y10T436/14; Y10T436/142222; Y10T436/143333

Claims Analysis

Total Claims: 26
Claim 1
Independent Claim 89 words
A synthetic heteropolymer comprising a single stranded nucleic acid molecule having at least a first and a second defined sequence segment, wherein the first defined sequence segment is capable of specifically and noncovalently binding to a first non-oligonucleotide molecule having a selected activity and the second defined sequence segment is capable of specifically and noncovalently binding to a second, different non-oligonucleotide molecule having a selected activity, wherein said first and second defined sequence segments are not known to be biological recognition sites for said first and second nonoligonucleotide molecules.
Claim 2
Dependent Claim 89 words
A synthetic heteropolymer comprising a single stranded nucleic acid molecule having at least a first and a second defined sequence segment, wherein the first defined sequence segment is capable of specifically and noncovalently binding to a first non-oligonucleotide molecule having a selected activity and the second defined sequence segment is capable of specifically and noncovalently binding to a second, different non-oligonucleotide molecule having a selected activity, wherein said first and second defined sequence segments are not known to be biological recognition sites for said first and second nonoligonucleotide molecules.
Claim 3
Dependent Claim 119 words
A synthetic heteropolymer comprising a single stranded nucleic acid molecule having at least a first and a second defined sequence segment, wherein the first defined sequence segment is not known to be a biological recognition site for nonoligonucleotide molecules and is capable of specifically and noncovalently binding to a non-oligonucleotide molecule having a selected activity and the second defined sequence segment is capable of hybridization to a selected nucleic acid sequence which does not hybridize to said first defined sequence segment, said first and second defined sequence segments bringing said nonoligonucleotide molecule and said nucleic acid sequence into proximity such that the binding or activity of said nonoligonucleotide molecule is modulated by binding of the selected nucleic acid sequence.
Claim 4
Dependent Claim 119 words
A synthetic heteropolymer comprising a single stranded nucleic acid molecule having at least a first and a second defined sequence segment, wherein the first defined sequence segment is not known to be a biological recognition site for nonoligonucleotide molecules and is capable of specifically and noncovalently binding to a non-oligonucleotide molecule having a selected activity and the second defined sequence segment is capable of hybridization to a selected nucleic acid sequence which does not hybridize to said first defined sequence segment, said first and second defined sequence segments bringing said nonoligonucleotide molecule and said nucleic acid sequence into proximity such that the binding or activity of said nonoligonucleotide molecule is modulated by binding of the selected nucleic acid sequence.
Claim 5
Dependent Claim 25 words
A multimolecular complex comprising a synthetic heteropolymer of claim 2 having a non-oligonucleotide molecule specifically bound to the first defined sequence segment of said heteropolymer.
Claim 6
Dependent Claim 35 words
The multimolecular complex of claim 3 wherein a selected activity of the non-oligonucleotide molecule specifically bound to the first defined sequence segment is modulated by hybridization of the second defined sequence segment of said heteropolymer.
Claim 7
Dependent Claim 33 words
The multimolecular complex of claim 3 wherein the affinity of the first defined sequence segment for the bound non-oligonucleotide molecule is modulated by hybridization of the second defined sequence segment of said heteropolymer.
Claim 8
Dependent Claim 72 words
A multivalent heteropolymeric hybrid structure comprising at least two synthetic heteropolymers, each synthetic heteropolymer being a single stranded nucleic acid molecule comprising at least a first and a second defined sequence segment, wherein said first defined sequence segment is not known to be a biological recognition site for nonoligonucleotide molecules and is capable of specifically and noncovalently binding to a non-oligonucleotide molecule and the second defined sequence segment being capable of hybridization.
Claim 9
Dependent Claim 72 words
A multivalent heteropolymeric hybrid structure comprising at least two synthetic heteropolymers, each synthetic heteropolymer being a single stranded nucleic acid molecule comprising at least a first and a second defined sequence segment, wherein said first defined sequence segment is not known to be a biological recognition site for nonoligonucleotide molecules and is capable of specifically and noncovalently binding to a non-oligonucleotide molecule and the second defined sequence segment being capable of hybridization.
Claim 10
Dependent Claim 23 words
The multivalent heteropolymeric hybrid structure of claim 6 wherein the second defined sequence segment of each synthetic heteropolymer comprises 5 to 40 nucleotides.
Claim 11
Dependent Claim 28 words
The multivalent heteropolymeric hybrid structure of claim 6 comprising two synthetic heteropolymers, each synthetic heteropolymer having a second defined sequence segment capable of hybridizing the two synthetic heteropolymers.
Claim 12
Dependent Claim 31 words
The multivalent heteropolymeric hybrid structure of claim 6 further comprising a linker oligonucleotide capable of hybridizing to the second defined sequence segment of each synthetic heteropolymer and joining the synthetic heteropolymers.
Claim 13
Dependent Claim 32 words
The multivalent heteropolymeric hybrid structure of claim 9 wherein the linker oligonucleotide comprises a duplex structure having single-stranded ends capable of hybridizing to the second defined sequence segments of the synthetic heteropolymers.
Claim 14
Dependent Claim 29 words
The multivalent heteropolymeric hybrid structure of claim 9 wherein the linker oligonucleotide comprises a triplex structure capable of hybridizing to the second defined sequence segments of the synthetic heteropolymers.
Claim 15
Dependent Claim 33 words
The multivalent heteropolymeric hybrid structure of claim 9 wherein the linker oligonucleotide comprises a branched-chain structure having defined sequence segments capable of hybridizing to the second defined sequence segments of the synthetic heteropolymers.
Claim 16
Dependent Claim 33 words
The multivalent heteropolymeric hybrid structure of claim 9 wherein the linker oligonucleotide comprises a circular structure having defined sequence segments capable of hybridizing to the second defined sequence segment of each synthetic heteropolymer.
Claim 17
Dependent Claim 35 words
A multimolecular complex comprising a multivalent heteropolymeric hybrid structure of claim 6 having a first non-oligonucleotide molecule specifically bound to the first defined sequence segment of the first synthetic heteropolymer of said heteropolymeric hybrid structure.
Claim 18
Dependent Claim 55 words
The multimolecular complex of claim 14 wherein the specific binding of the first non-oligonucleotide molecule to the first defined sequence segment of the first synthetic heteropolymer of said heteropolymeric hybrid structure modulates the affinity of the first defined sequence segment of a second synthetic heteropolymer of said heteropolymeric hybrid structure for a second non-oligonucleotide molecule.
Claim 19
Dependent Claim 59 words
The multimolecular complex of claim 14 wherein the specific binding of the first non-oligonucleotide molecule to the first defined sequence segment of the first synthetic heteropolymer of said heteropolymeric hybrid structure modulates a selected activity of a second, different non-oligonucleotide molecule specifically bound to the first defined sequence segment of the second synthetic heteropolymer of said heteropolymeric hybrid structure.
Claim 20
Dependent Claim 34 words
The multimolecular complex of claim 14 further comprising a second non-oligonucleotide molecule having a selected activity specifically bound to the first defined sequence segment of the second synthetic heteropolymer of said heteropolymeric hybrid structure.
Claim 21
Dependent Claim 96 words
A multivalent heteropolymeric hybrid structure comprising a first synthetic heteropolymer which is a single stranded nucleic acid molecule having at least a first and second defined sequence segment, wherein the first defined sequence segment is not known to be a biological recognition site for nonoligonucleotide molecules and is capable of specifically and noncovalently binding to a non-oligonucleotide molecule having a selected activity and wherein the second defined sequence segment is capable of hybridization, and a second synthetic heteropolymer which is a single stranded nucleic acid molecule having at least two defined sequence segments capable of hybridization.
Claim 22
Dependent Claim 96 words
A multivalent heteropolymeric hybrid structure comprising a first synthetic heteropolymer which is a single stranded nucleic acid molecule having at least a first and second defined sequence segment, wherein the first defined sequence segment is not known to be a biological recognition site for nonoligonucleotide molecules and is capable of specifically and noncovalently binding to a non-oligonucleotide molecule having a selected activity and wherein the second defined sequence segment is capable of hybridization, and a second synthetic heteropolymer which is a single stranded nucleic acid molecule having at least two defined sequence segments capable of hybridization.
Claim 23
Dependent Claim 26 words
A multimolecular complex comprising a synthetic heteropolymer of claim 1 having a first non-oligonucleotide molecule specifically bound to the first defined sequence segment of said heteropolymer.
Claim 24
Dependent Claim 39 words
The multimolecular complex of claim 19 wherein the specific binding of the first non-oligonucleotide molecule to the first defined sequence segment modulates the affinity of the second defined sequence segment of said heteropolymer for a second, different non-oligonucleotide molecule.
Claim 25
Dependent Claim 42 words
The multimolecular complex of claim 19 wherein the specific binding of the first non-oligonucleotide molecule to the first defined sequence segment modulates a selected activity of a second, different non-oligonucleotide molecule specifically bound to the second defined sequence segment of said heteropolymer.
Claim 26
Dependent Claim 23 words
The multimolecular complex of claim 19 further comprising a second non-oligonucleotide molecule specifically bound to the second defined sequence segment of said heteropolymer.

References Cited (Backward Citations)

US3977941A Cited
US4601981A Cited
US4203802A Cited
US5527690A Cited
US5118801A Cited
EP0491059A1 Cited
US5437977A Cited
US5270163A Cited
US5434257A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 2000-08-11 2001-02-10 2001-08-12 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2004-08-11 2005-02-10 2005-08-12 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2008-08-11 2009-02-10 2009-08-12 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag